Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Once users stop taking Mounjaro, their appetite is no longer suppressed, and there's a decent chance that they will revert back to old eating habits and put the weight back on, but there are also ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Eli Lilly's Mounjaro saw a dramatic increase in sales, with numbers doubling in just a month. Novo Nordisk, on the other hand, has taken a significant step by submitting a higher dose of its obesity ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The demand for obesity drugs in India surges as Eli Lilly and Novo Nordisk vie for market share. Meanwhile, President Trump ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...